<DOC>
	<DOCNO>NCT00619034</DOCNO>
	<brief_summary>The purpose study determine diabetic retinopathy treat prostaglandin analogue , prostaglandin synthesis inhibitor carbonic anhydrases inhibitor .</brief_summary>
	<brief_title>Pharmacological Intervention Diabetic Retinopathy</brief_title>
	<detailed_description>Disturbances retinal perfusion believe involved pathophysiology diabetic retinopathy . These disturbance may due change basal diameter retinal arteriole disturbance autoregulation diameter vessel blood pressure retinal metabolism change . In vitro study show prostaglandin carbonic anhydrases inhibitor involve tone regulation retinal arteriole , unknown whether find relevant clinical practice . This test vivo retinal vessel analyzer measure dynamic retinal vessel diameter change .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Dorzolamide</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Diabetes type 1 moderate diabetic retinopathy/healthy Blood pressure &lt; 135/85 mmHg Eye disease ( exclude diabetic retinopathy ) Allergic Kidney disease Liver disease Severe asthma Heart disease Hypertension arterial Users drug influence metabolism prostaglandins carbon dioxide Pregnant breastfeed woman woman n't use secure contraception Persons ca n't without contact lens treat eye .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>